百济神州发布2025年度业绩 收入及利润：2025年全年总收入53亿美元、同比增长40%，Q425总收入15亿美元，同比增长33%。 #2025年第四季度和全年GAAP净利润为6700万美元和2.87亿美元，与上年同期净亏损相比分别增加2.18亿美元和 9.32亿美元。 2025年全年GAAP净利润包括7600万美元的股权投资减值费用、2500万美元的非经常性税务项目费用、以及在特定 司法管辖区因时间性因素产生的2000万美元税务费用。 由于相关费用主要发生在第四季度，对四季度利润影响较大。 指引：#2026年总收入指引区间62亿-64亿美元-对应同比增速区间17%-21% ，毛利率将位于80%区间的高 位，GAAP经营利润为7-8亿美元，非GAAP经营利润为14-15亿美元。 百济神州发布2025年度业绩 收入及利润：2025年全年总收入53亿美元、同比增长40%，Q425总收入15亿美元，同比增长33%。 #2025年第四季度和全年GAAP净利润为6700万美元和2.87亿美元，与上年同期净亏损相比分别增加2.18亿美元和 9.32亿美元。 2025年全年GAAP净利润包括7600万美元的股权投资减值费用 ...

创新药龙头重磅业绩利好！百济神州2月26日发布2025年度业绩快报，全年营收382.05亿元，同比增 40.4%；归母净利润14.22亿元，实现扭亏为盈。 值得一提的是，这是这家创新药龙头公司首次实现年度盈利，也是中国创新药企全球化发展的重要里程 碑。 公告显示，百济神州业绩增长得益于核心产品放量，2025年百悦泽全球销售额280.67亿元，同比增长 48.8%。此外，公司多款候选药物进入临床关键阶段，百悦达在中国获批上市，BGB-B2033获FDA快速 通道资格认定。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏创新药机遇，借道ETF效率更高！ 投纯正创新药，认准T+0利器——港股通创新药ETF（520880）及其场外联接基金（025221），100%布 局创新药研发类公司，前十大权重股占比超七成，龙头属性突出。 降低波动 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- ...

【今日头条】 中国AI调用量首超美国，四款大模型霸榜全球前五 2月，中国AI的模型调用量爆发式增长，首次超过美国。全球最大的AI模型API聚合平台OpenRouter数 据显示，9日~15日这周，中国模型以4.12万亿Token的调用量，首次超过同期美国模型的2.94万亿 Token。16日~22日这周，中国模型的周调用量进一步冲高至5.16万亿Token，三周大涨127%，而同期美 国模型调用量跌至2.7万亿Token。与此同时，全球调用量排名前五的模型中，中国模型占据四席，这股 强大的增长动能，并非依赖单一爆款产品，而是中国AI厂商集群式崛起。 Token是AI模型处理文本的最小单位。相比用户数，Token调用量是更能真实反映AI模型使用强度、用 户粘性及商业价值的关键指标。中国模型厂商，正凭借快速迭代和成本优势占领全球市场，国产算力需 求正经历指数级增长。 四款登榜大模型：阿里通义千问(Qwen3);深度求索(DeepSeek-V3.1);智谱GLM-4.6/4.7;月之暗面Kimi K2.5。 纳斯达克中国金龙指数收跌1.78% 隔夜美股道指涨17.05点，涨幅为0.03%，报49499.20点;纳指 ...

2月26日晚间，百济神州-U（SH688235，股价263.44元，市值4058.76亿元）发布2025年度业绩快报，公司全年实现营业总收入382.05亿元，同比增长 40.4%；归属于母公司所有者的净利润14.22亿元，较上年同期的净亏损49.78亿元实现扭亏为盈。 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 38,204,601 | 27,213,955 | 40.4 | | 其中:产品收入 | 37,769,870 | 26,993,842 | 39.9 | | 营业利润 | 2,562,102 | -4.161.996 | 不适用 | | 利润总额 | 2,558,155 | -4,162,650 | 不适用 | | 归属于母公司所有者的 | 1,422,185 | -4.978.287 | 不适用 | | 净利润 | | | | | 归属于母公司所有者的 扣除非经常性损益的净 | 1,381,283 | -5,379,293 | 不适用 | | 利润 | | | | 图片来源：百济神州-U公告 《每日经济新 ...

百济神州表示，报告期内，公司营业收入增加40.4%，主要得益于百悦泽，以及安进公司授权产品和百 泽安的销售增长。公司实现盈利主要得益于产品收入增长和费用管理推动的经营效率提升。 北京商报讯（记者 丁宁）2月26日晚间，百济神州（688235）发布2025年度业绩快报显示，公司2025年 实现营业收入382.05亿元，同比增长40.4%；归属净利润约为14.22亿元，同比扭亏。 ...

百济神州(06160.HK)公告，2025年第四季度，全球总收入达15亿美元，同比增长33%；全年全球总收入 达53亿美元，同比增长40%。百悦泽第四季度全球销售额达11亿美元，同比增长38%；全球年销售额达 39亿美元，同比增长49%。第四季度和全年，GAAP稀释每股美国存托股份(ADS)收益分别为0.58美元和 2.53美元；非GAAP稀释每股ADS收益分别为1.95美元和8.09美元。2026年全年总收入指引为62亿美元至 64亿美元之间。 来源：滚动播报 ...

格隆汇2月26日｜百济神州(6160.HK)公告，2025年第四季度，全球总收入达15亿美元，同比增长33%； 全年全球总收入达53亿美元，同比增长40%。百悦泽第四季度全球销售额达11亿美元，同比增长38%； 全球年销售额达39亿美元，同比增长49%。第四季度和全年，GAAP稀释每股美国存托股份(ADS)收益 分别为0.58美元和2.53美元；非GAAP稀释每股ADS收益分别为1.95美元和8.09美元。2026年全年总收入 指引为62亿美元至64亿美元之间。 ...

Group 1 - The year 2025 marks a milestone for the company, celebrating its 15th anniversary and entering a clearer phase in its globalization process [2] - The company achieved significant global growth in the past year, reaching a critical profitability turning point, with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [2] - The company launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotukral), which is now commercially available [2] Group 2 - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [3] - In India, the company's two self-developed products have benefited over 1,500 patients, receiving positive clinical feedback [3] - The company is expanding its global footprint by supporting local commercialization efforts in Indonesia and providing PD-1 inhibitors for clinical trials in sub-Saharan Africa [3] Group 3 - The company's goals for 2026 remain clear: to continue pipeline expansion centered on science and to enhance drug accessibility for patients in more countries [4] - The commitment to making innovations accessible to more patients is seen as a long-term investment and a driving force for the company [4] - The company emphasizes the importance of collaboration with industry partners to gather diverse experiences and wisdom from different regions to improve patient outcomes globally [4]

Group 1 - The report highlights a significant divergence in the performance of various sub-sectors within the pharmaceutical industry in 2025, with the CXO and innovative drug-related sectors showing substantial growth, while the medical service sector is expected to gradually recover in 2026 due to a low base effect from 2025 [2][6][58] - The overall performance of the A-share market was positive in 2025, with the pharmaceutical and biological sector ranking 10th with a growth of 34.95%, while the CXO sector led with a growth of 58.71% [6][15] - The report emphasizes the importance of "product-driven" companies, which are expected to enter a profitability cycle as they recover from the impacts of centralized procurement and increase their R&D investments [2][29] Group 2 - The innovative drug sector is projected to continue its upward trend, with business development (BD) opportunities abroad being a key focus, indicating the global competitiveness of Chinese innovative drugs [30][34] - The medical device sector is also expected to follow a similar recovery path as innovative drugs, with increasing R&D investments and a growing number of approved innovative medical devices [43][45] - The medical service sector, despite facing short-term pressures, is anticipated to gradually recover in 2026, supported by an aging population and increasing demand for healthcare services [58] Group 3 - The report suggests specific companies to watch in various sectors, including medical devices (e.g., Sanyou Medical, Aikang Medical), innovative drugs (e.g., Innovent Biologics, Kintor Pharmaceutical), and medical services (e.g., Aier Eye Hospital, Tongce Medical) [2][29] - The report notes that the pharmaceutical sector's overall valuation remains at a historical low, with a price-to-earnings ratio of 30.82 times as of October 31, 2025, indicating potential for upward adjustment [19][20] - The report highlights the importance of key product advancements and performance realization in the innovative drug sector, particularly for products like PD-1/VEGF, which have shown promising clinical data and significant market interest [39][40]

Core Viewpoint - The article discusses the increasing interaction between Chinese innovative drugs and global patients, highlighting the appeal of CAR-T therapy in China for international cancer patients due to lower costs and efficient treatment processes [1][3][4]. Group 1: CAR-T Therapy in China - CAR-T therapy is a personalized treatment that enhances the ability of T-cells to recognize and kill tumors, with significant development concentrated in China and the US [3]. - The cost of CAR-T drugs in China ranges from 1 million to 1.3 million yuan, approximately one-third of the price in the US, making it a more attractive option for patients [4][5]. - Over the past year, more than 100 overseas patients have consulted with medical institutions in China, with around 90% of completed CAR-T treatments being for international patients [6]. Group 2: Growth of China's Oncology Drug Ecosystem - China's oncology sector has attracted substantial R&D funding, with advancements spanning from early screening to late-stage treatment [7]. - The approval of new indications for existing drugs, such as the combination therapy for non-small cell lung cancer, showcases the rapid development in the oncology field [7]. - The increasing recognition of Chinese pharmaceutical innovation is evidenced by the number of breakthrough therapy designations granted by the FDA to Chinese products [11]. Group 3: International Expansion of Chinese Drugs - Chinese companies are increasingly recognized for their innovation, with significant international collaborations and licensing agreements, such as the partnership between Innovent Biologics and Takeda Pharmaceuticals [10]. - The global market for Chinese CAR-T products is expanding, with companies like Legend Biotech achieving substantial sales figures in the US [10]. - The trend of Chinese pharmaceutical companies seeking international markets is driven by the need for growth outside the competitive domestic landscape [13]. Group 4: Challenges and Opportunities - While the Chinese pharmaceutical industry is making strides, challenges remain in establishing a robust international presence and navigating regulatory environments [12]. - The potential for growth in medical tourism in China is significant, but improvements in visa policies and treatment timelines are necessary to enhance competitiveness [8]. - The future of China's innovative drug sector is uncertain, with investors closely monitoring government policies and market dynamics [13].